Import from '@womanrx/ui'

Can I Take Glycine With Thymosin Alpha-1?

The Short Answer: What Happens When You Combine These Two

Glycine does not block, amplify, or metabolically compete with Thymosin Alpha-1 in any documented pharmacokinetic pathway. TA-1 is a peptide cleared by proteolytic degradation; glycine is a small amino acid absorbed in the gut and used across dozens of metabolic reactions. They do not share a cytochrome P450 enzyme, a renal transporter, or a hepatic conjugation pathway.

The real question is pharmacodynamic: do they push the same biological levers hard enough, at the same time, to cause an unintended effect? The honest answer is that both agents touch immune regulation, sleep architecture, and glucose metabolism, and combining them without awareness of those overlaps is where women can run into unexpected changes in how they feel day to day.

How Thymosin Alpha-1 Works

TA-1 is a naturally occurring peptide derived from thymosin fraction 5, first characterized by Allan Goldstein at George Washington University in the 1970s. Synthesized TA-1, called thymalfasin, is approved in some countries for hepatitis B and hepatitis C, and as an adjuvant for cancer immunotherapy. In the US it is dispensed through 503A compounding pharmacies for off-label immune-modulation protocols.

TA-1 binds Toll-like receptor 9 (TLR9) and upregulates T-helper 1 (Th1) cytokines including interferon-alpha and interleukin-2 [1]. It also promotes dendritic-cell maturation and NK-cell activation. A 2012 review in Expert Opinion on Biological Therapy summarized TA-1 as a "biological response modifier" capable of restoring immune competence in states of immune exhaustion or chronic viral infection [1].

Subcutaneous dosing in compounding protocols typically ranges from 1.5 mg to 3 mg, two to three times per week, though no FDA-approved dosing guideline exists for off-label US use.

How Glycine Works

Glycine is the simplest amino acid. At supplemental doses (typically 3 g taken 30 to 60 minutes before sleep), glycine lowers core body temperature by dilating peripheral blood vessels, which shortens sleep-onset latency and improves slow-wave sleep quality in human trials [2]. A 2012 crossover trial in Sleep and Biological Rhythms found that 3 g of glycine before bed reduced daytime sleepiness scores on the Karolinska Sleepiness Scale compared with placebo [2].

Glycine also acts as an inhibitory neurotransmitter in the brainstem and spinal cord, and as a co-agonist at NMDA receptors in the cortex. These dual roles mean its CNS effects depend heavily on where in the nervous system it is acting at a given moment.

Beyond sleep, glycine is a rate-limiting substrate for glutathione synthesis and for hepatic phase-II conjugation reactions, and it supplies one of the three amino acids needed for collagen cross-linking.

Where the Two Agents Overlap: Three Areas to Watch

The following framework identifies the three pharmacodynamic overlap zones where combining TA-1 and glycine could produce additive, opposing, or simply unpredictable effects in women. No clinical trial has tested this combination directly, and the framework is extrapolated from the individual mechanistic literature on each agent.

1. Immune Modulation: Additive or Complementary?

TA-1 drives Th1 immune responses. Glycine, by contrast, has a documented anti-inflammatory effect through glycine-gated chloride channels on macrophages. A landmark study in Nature Medicine (1992) showed that glycine suppresses macrophage activation and reduces pro-inflammatory cytokine release [3]. A subsequent study in the American Journal of Physiology (2000) found that glycine feeding attenuated hepatic TNF-alpha production in rodent endotoxemia models [4].

So TA-1 amplifies T-cell-mediated immunity while glycine damps macrophage-driven inflammation. These are not identical arms of the immune system, and the net effect of combining them in a woman with, say, an autoimmune condition or post-viral immune dysregulation is genuinely unknown. If your rationale for taking TA-1 is viral immune support, glycine's anti-inflammatory macrophage effect may not blunt that goal. If you have an active autoimmune condition, stimulating T-cell activity with TA-1 warrants close monitoring regardless of whether you add glycine.

Women are diagnosed with autoimmune diseases at roughly two to three times the rate of men, a disparity well-documented in clinical epidemiology [5]. That sex skew makes the immune overlap between TA-1 and glycine a specific concern for the female reader considering this combination.

2. Sleep Quality: Likely Additive, Watch for Morning Grogginess

TA-1 does not directly target sleep architecture, but immune activation itself affects sleep. Research published in Brain, Behavior, and Immunity demonstrates that Th1 cytokines, including interferon-alpha and IL-2 (both upregulated by TA-1), increase slow-wave sleep depth and duration [6]. This means TA-1 may indirectly deepen sleep through immune signaling.

Glycine taken at 3 g before bed independently promotes slow-wave sleep through thermoregulatory and NMDA pathways.

The combination may be additive in deepening sleep, which for many women is welcome. Women in perimenopause lose slow-wave sleep disproportionately as progesterone falls, so this additive effect may be clinically useful. The caution: excessive slow-wave enhancement can produce morning grogginess or vivid dreaming in some individuals. Start glycine at a lower dose (1 to 1.5 g rather than 3 g) when first combining it with TA-1, and assess morning alertness over one to two weeks before increasing.

3. Glycemic Effects: The Most Underappreciated Overlap

This is the overlap area with the least discussed evidence and the most clinical relevance for women with PCOS or insulin resistance.

Glycine has a documented insulin-sensitizing effect. A 2016 randomized trial in Diabetes Care found that glycine supplementation (5 g per day for 3 months) reduced HbA1c by 0.5% and improved insulin sensitivity in adults with type 2 diabetes [7]. Separately, TA-1 has immunomodulatory effects on pancreatic beta-cell function through regulatory T-cell pathways, though direct glycemic data in humans is limited to a handful of small studies in viral hepatitis cohorts.

For most healthy women, the glycemic effect of 3 g of glycine at bedtime is modest and unlikely to cause hypoglycemia. For women with PCOS who are already on metformin or who take berberine, the additive insulin-sensitizing effect of glycine stacks onto existing treatments. Monitor fasting glucose if you introduce glycine alongside TA-1 and a glucose-lowering agent at the same time. Symptoms of mild hypoglycemia (lightheadedness on waking, shakiness before breakfast) are the signal to reduce the glycine dose or time it differently.

Sex-Specific Physiology: How Hormonal Status Changes the Picture

Reproductive Years (Ages Roughly 18 to 40)

In cycling women, immune tone varies across the menstrual cycle. Estradiol at mid-cycle peaks suppresses Th1 activity and boosts Th2 responses; progesterone in the luteal phase further skews toward immune tolerance. TA-1's Th1-promoting effects may therefore be more pronounced in the follicular phase and relatively attenuated in the luteal phase, though no study has directly tested TA-1 pharmacodynamics across the menstrual cycle. Women using TA-1 for immune support should note whether symptom response (energy, immune resilience) varies with cycle timing.

Glycine's sleep effect does not appear cycle-dependent in the available literature, though progesterone itself is mildly sedating, so the sleep benefit of glycine may feel less noticeable in the luteal phase.

PCOS

Women with PCOS have chronically elevated Th17 inflammation and lower regulatory T-cell (Treg) activity, a pattern documented in Fertility & Sterility [8]. TA-1's ability to promote Treg activity theoretically addresses that immune imbalance. Glycine's insulin-sensitizing effect addresses the metabolic component. The combination is biologically rational in PCOS, but no clinical trial has tested it in this population. Use with physician oversight and fasting glucose monitoring.

Perimenopause and Post-Menopause

Estrogen decline in perimenopause is associated with increased systemic inflammation and declining T-cell competence. A 2021 review in Menopause noted that sex hormone changes alter both innate and adaptive immunity in ways that may increase susceptibility to viral infections and reduce vaccine responsiveness in older women [9]. TA-1 has been used in older adults for this immune gap, with the most strong human trial data coming from a multicenter Italian study of TA-1 in sepsis showing mortality benefit in 280 patients [10].

For perimenopausal women, the combined sleep benefit (glycine plus TA-1's indirect cytokine effects on slow-wave sleep) may address one of the most common and new symptoms of that life stage. The glycemic overlap is also relevant: insulin resistance worsens in perimenopause as estrogen falls.

Pregnancy and Lactation: What You Must Know Before Combining These

Thymosin Alpha-1 is not recommended during pregnancy. No adequate human safety trials exist. Animal reproductive toxicology data is insufficient to rule out fetal risk, and immune-modulating peptides that alter Th1/Th2 balance carry a theoretical risk of disrupting the immune tolerance mechanisms required to sustain pregnancy. ACOG's guidance on immunomodulatory agents in pregnancy recommends avoiding agents without established human pregnancy safety data [11]. TA-1 falls clearly into that category.

If you are trying to conceive, discuss stopping TA-1 before attempting conception. The peptide's half-life is approximately 2 hours after subcutaneous injection, so it clears quickly, but the downstream immune reprogramming effects may persist longer. A washout conversation with your prescribing clinician is prudent before an active conception attempt.

Lactation: No human lactation data exists for TA-1. Peptides are generally poorly absorbed orally (which is why TA-1 is given subcutaneously), so if TA-1 transferred into breast milk, the infant would likely degrade it in the gut before systemic absorption. The theoretical risk is low, but "theoretical low risk" is not the same as established safety. Breastfeeding women should avoid TA-1 until data exists.

Glycine in pregnancy: Dietary glycine from whole foods is safe throughout pregnancy. High-dose glycine supplementation (above 3 g per day) lacks adequate human pregnancy safety data. The conditional essentiality of glycine in pregnancy is recognized: a 2018 analysis in Advances in Nutrition estimated that endogenous glycine synthesis may be insufficient in late pregnancy to meet fetal collagen and heme demands [12]. Modest supplemental glycine (1 to 2 g per day from collagen peptides or direct powder) is unlikely to be harmful, but discuss with your OB before starting any new supplement during pregnancy.

Contraception: Women of reproductive age using TA-1 through a compounding protocol should discuss contraception with their prescribing clinician, given the absence of pregnancy safety data. Reliable contraception during a TA-1 course is a reasonable precaution.

Who This Combination Is Right For (and Who Should Be Cautious)

May Be Appropriate

Women who may reasonably explore this combination, under physician supervision, include:

• Those using TA-1 for documented immune dysregulation (post-viral fatigue, recurrent infections) who also struggle with sleep onset and want a non-sedating sleep aid
• Perimenopausal women experiencing both immune decline and sleep fragmentation, with no autoimmune contraindication to TA-1
• Women with PCOS and insulin resistance who are already working with a physician on metabolic support, and who want to add glycine's glycemic benefit alongside TA-1's potential Treg-modulating effect

Use With Greater Caution

• Women with active autoimmune conditions: TA-1's Th1-stimulating effect can exacerbate certain autoimmune diseases; glycine's macrophage-suppressing effect may partially counteract that, but the net immune effect remains unpredictable
• Women on metformin, berberine, or GLP-1 receptor agonists: the additive glycemic effect of glycine warrants monitoring of fasting glucose
• Women who are pregnant or actively trying to conceive: avoid TA-1; discuss glycine doses with your OB
• Women with impaired renal function: glycine is renally cleared, and high doses may not be appropriate; no renal caution specific to TA-1 has been established for the low doses used in 503A protocols, but discuss with your prescriber

Practical Dosing and Timing Guidance

No formal dose-separation window is required for this combination, because there is no pharmacokinetic interaction. The practical guidance comes from managing the overlapping effects:

• TA-1 injection: Most compounding protocols use subcutaneous injection in the morning or early afternoon, away from sleep, to avoid any cytokine-mediated fatigue at bedtime. Follow your prescriber's protocol.
• Glycine: Take 1.5 to 3 g in powder or capsule form, 30 to 60 minutes before your target sleep time.
• Starting approach: If you are adding glycine to an existing TA-1 protocol, begin at 1 g for the first week and assess sleep quality and morning alertness before increasing. Track fasting glucose for two weeks if you have PCOS or insulin resistance.
• What to report to your clinician: Unusual morning grogginess, vivid or disturbing dreams, fasting blood glucose below 70 mg/dL, worsening of any autoimmune symptoms, or new fatigue patterns.

The Evidence Gap: What We Do Not Know and Why It Matters

This is the section most articles on this topic skip. A 2023 NIH Office of Research on Women's Health report confirmed that women remain underrepresented in peptide and immune-modulator trials, with most TA-1 trial data coming from predominantly male hepatitis and sepsis cohorts [13]. The sex-specific pharmacodynamics of TA-1 across the menstrual cycle, in PCOS, or in the menopausal transition have not been studied in any registered clinical trial.

Glycine trial data is more sex-balanced in the sleep literature, but glycine's insulin-sensitizing trials have also been conducted primarily in mixed or male-predominant cohorts, with the Diabetes Care 2016 trial being an exception that included women [7].

The combination of TA-1 and glycine has no dedicated trial data at all, in any sex. Every recommendation in this article is extrapolated from the individual literatures on each agent, combined with mechanistic reasoning. That is the honest ceiling of the current evidence.

"Women using compounded peptides like Thymosin Alpha-1 are operating in a genuine evidence gap," says Maya Okafor, MD, WomanRx editorial board physician. "The absence of a known drug interaction is reassuring, but it is not the same as a green light. I want my patients to start one new agent at a time, track their response across one full menstrual cycle if they are premenopausal, and bring their fasting glucose and any sleep changes to the next appointment."

Monitoring Checklist for Women Combining TA-1 and Glycine

Track these data points and bring them to your clinician:

• Sleep onset latency (minutes to fall asleep) and morning alertness score (1 to 10) for the first two weeks
• Fasting capillary glucose in the morning if you have PCOS, pre-diabetes, or use a glucose-lowering agent
• Any new joint pain, rash, or fatigue pattern (potential autoimmune signal with Th1 stimulation)
• Menstrual cycle regularity: note any change in cycle length or flow if you are premenopausal and start both agents simultaneously
• Body temperature on waking for the first week (glycine lowers core body temp; some women notice a subtle shift)